Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.60    -0.35 (-4.00%)
Bid:
8.20
Ask:
9.00
Spread: 0.80 (9.756%)
Market Cap: £55.03m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Directorate Change

18 Feb 2014 07:00

RNS Number : 2823A
Kromek Group PLC
18 February 2014
 



 

Kromek Group plc

("Kromek" or "the Company")

Directorate Change

 

Kromek, a supplier of patented radiation detection technologies to the medical, security and nuclear markets, announces that Ms. Maria Charlotta Ginman-Jones (known as Ms. Charlotta Ginman) has been appointed to the Company's Board as a Non-Executive Director with immediate effect.

 

Ms. Ginman, aged 48, will chair the Company's Audit Committee and brings with her substantial experience in financial and operational management gained during her successful executive career in the global telecommunications and investment banking sectors.

 

Currently a Non-Executive Director of Wolfson Microelectronics, and a member of Wolfson's Audit Committee, Ms. Ginman began her career at Ernst & Young LLP joining in 1989 until 1994, and was then appointed to a series of senior roles in investment banking with JP Morgan, Deutsche Bank and UBS.

 

During a career with Nokia Corporation, Ms. Ginman held many different roles, beginning as a business controller in the company's imaging division and progressing to the role of director of finance and control of the company's service business. Ms. Ginman has overseen a number acquisitions during her tenure at Nokia and became Chief Financial Officer of Nokia's luxury mobile phone division, Vertu Corporation Ltd, in 2009. Ms Ginman led the carve out of Vertu Corporation Ltd from Nokia and successfully sold the business to a private equity group.

 

A chartered accountant, Ms. Ginman also holds an MSc in Economics from the Swedish School of Economics and Business Administration in Helsinki.

 

Commenting on the announcement, Arnab Basu, CEO of Kromek, commented: "We are very pleased to welcome Charlotta to our Board. We will benefit greatly from her knowledge and experience that she has gained during an impressive career and her appointment further strengthens our Board."

 

"Charlotta joins Kromek at a very exciting time. Since joining AIM, we have accelerated our development and we are building on the success achieved in recent years, as we work to realise the value of our world-class technology platform."

 

Previous Directorships

Wolfson Microelectronics plc, Non-executive Director

Current Directorships

Ms. Ginman is not currently a director of any other company.

 

There is no other information that is required to be disclosed under Schedule 2 paragraph (g) of the AIM Rules in relation to the appointments of Ms. Ginman.

 

-ends-

 

For further information, please contact:

Kromek Group Plc

Arnab Basu, CEO

Derek Bulmer, CFO

 

Tel: 01740 626060

Panmure Gordon

As Nominated Adviser and Broker

Corporate Finance

Freddy Crossley/ Grishma Patel

Broking

Adam Pollock/ Charlie Leigh-Pemberton

 

Tel: 020 7886 2500

Tavistock Communications

Matt Ridsdale

Andrew Dunn

Tel: 020 7920 3150

 

About Kromek

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 70 granted patents and 110 pending applications.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

Currently, the Group has over a hundred full time employees across its global operations.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLFLTFEIDLIS
Date   Source Headline
8th Dec 20207:00 amRNSContract extensions for D3S products
3rd Dec 20207:00 amRNSKromek launches the D5 RIID radiation detector
2nd Nov 20207:00 amRNSKromek wins new sector-leading global OEM customer
2nd Nov 20207:00 amRNSResult of AGM
29th Oct 20207:00 amRNSDirectorate Change
14th Oct 20207:00 amRNSKromek CZT technology to improve cancer surgery
9th Oct 20204:41 pmRNSSecond Price Monitoring Extn
9th Oct 20204:36 pmRNSPrice Monitoring Extension
8th Oct 20205:28 pmRNSHolding(s) in Company
8th Oct 20204:44 pmRNSNotice of AGM and Publication of Annual Report
8th Oct 202012:58 pmRNSDirector Share Purchase
8th Oct 20207:00 amRNSAppointment of Non-executive Director
7th Oct 202011:13 amRNSDirector Share Purchase
7th Oct 202011:00 amRNSPrice Monitoring Extension
7th Oct 20207:00 amRNSFinal Results
28th Sep 20203:00 pmRNSHolding(s) in Company
17th Sep 20201:53 pmRNSHolding(s) in Company
27th May 20207:00 amRNSKromek awarded new DARPA bio-surveillance contract
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:36 pmRNSPrice Monitoring Extension
1st May 20209:05 amRNSSecond Price Monitoring Extn
1st May 20209:00 amRNSPrice Monitoring Extension
1st May 20207:00 amRNSFull Year Trading Update and Response to COVID-19
27th Apr 202010:57 amRNSHolding(s) in Company
21st Apr 20207:00 amRNSKromek receives Queen’s Award
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSKromek to produce ventilators to fight COVID-19
20th Mar 202010:52 amRNSHolding(s) in Company
18th Feb 20204:15 pmRNSHolding(s) in Company
27th Jan 202012:42 pmRNSSite visit by International Trade Secretary
9th Jan 20204:55 pmRNSHolding(s) in Company
27th Dec 20197:00 amRNSHolding(s) in Company
17th Dec 20197:00 amRNSDirector Share Purchase
12th Dec 20197:00 amRNSDirector Share Purchases
11th Dec 20197:00 amRNSInterim Results
5th Dec 20197:00 amRNSNotice of Results
4th Dec 20195:25 pmRNSHolding(s) in Company
26th Sep 20191:14 pmRNSResult of AGM
24th Sep 20197:00 amRNSKromek awarded two contracts for D3S products
30th Aug 20191:50 pmRNSNotice of AGM and Publication of Annual Report
1st Jul 20197:00 amRNSNew contracts for D3S in UK, US and Europe
27th Jun 20197:00 amRNSFinal Results
7th May 20197:00 amRNSTrading Update
1st May 20197:00 amRNSSecurity screening contract order expansion
29th Mar 20194:51 pmRNSChange of Adviser
18th Mar 20195:50 pmRNSDirector Dealings Correction
28th Feb 20191:00 pmRNSHolding(s) in Company
28th Feb 20191:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.